MOLORE RESIL: Open Payments
NPI 1891239091 · BROCKTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,224 in 41 payments from 9 companies in 2025. Trend: 2023 $681 · 2024 $1,135 · 2025 $1,224
Food & beverage: $1,224
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $556 |
| Otsuka America Pharmaceutical, Inc. | 8 | $291 |
| Lilly USA, LLC | 6 | $145 |
| Novo Nordisk Inc | 3 | $63 |
| PFIZER INC. | 2 | $59 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Exact Sciences Corporation | 1 | $27 |
| Amgen Inc. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $21 |
Products named: FARXIGA, REXULTI, BREZTRI, AIRSUPRA, JARDIANCE, ZEPBOUND, ZORYVE, Saxenda.
Industry payments across MA — which companies pay providers there.
